What is NMTC's health score?

NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) has a TradeApes health score of 46 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is NMTC's estimated fair value?

Based on our 5-year discounted cash flow model, NEUROONE MEDICAL TECHNOLOGIES Corp's estimated fair value is $2.16 per share, representing a -39.1% downside from the current price. This is a model estimate, not a price target or investment recommendation.

Is NMTC undervalued or overvalued?

Our model currently rates NMTC as Overvalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for NMTC... Refresh in a moment for the full analysis.

NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)

Healthcare Overvalued low mixed

$3.55

Updated: 2026-05-30

TradeApes Score

Financial Strength

55 Mixed

Operating Trend

63 Healthy

Relative Value

40 Weak

Capital Allocation

20 Stressed

Risk

35 Weak

Est. Fair Value $2.16

DCF Upside -39.1%

Sector Rank #2843 of 6585

Key Findings

+ Strong revenue growth — sales up more than 20% year over year

Unlock Full Report →

− Significant dilution — share count up more than 5% year over year

Unlock Full Report →

1 free score card remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.